What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
The current melanoma staging system does not always reflect actual survival outcomes. In some cases, patients with thick but ...
Increased diagnostic accuracy and wider availability of high-end ocular imaging are significant drivers to the uveal melanoma treatment market. High-resolution optical coherence tomography, multimodal ...
A form of T-cell therapy targeting a highly expressed antigen in uveal melanoma, a rare form of the disease, appears to be tolerable and efficacious, even though the tumors are considered to be ...
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, announced the first reported median overall survival ...
Servier and IDEAYA Biosciences (IDYA) enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for ...
Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with metastatic melanoma. The biotech previously shared progression-free survival ...
Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...
Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...
(RTTNews) - Replimune Group, Inc. (REPL), a clinical-stage biotechnology company, on Wednesday announced the first patient has been dosed in two clinical trials evaluating RP2, its oncolytic ...
Background Metabolic factors and obesity may influence the development and progression of cancer. In this study, we examine their association with the risk of developing metastases of uveal melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results